Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

2016; Massachusetts Medical Society; Volume: 374; Issue: 17 Linguagem: Inglês

10.1056/nejmoa1516282

ISSN

1533-4406

Autores

Philippe Moreau, Tamás Masszi, Norbert Grząśko, Nizar J. Bahlis, Markus Hansson, Luděk Pour, Irwindeep Sandhu, Peter Ganly, Bartrum W. Baker, Sharon Jackson, Anne-Marie Stoppa, David R. Simpson, Peter Gimsing, Antonio Palumbo, Laurent Garderet, Michèle Cavo, Shaji Kumar, Cyrille Touzeau, Francis K. Buadi, Jacob P. Laubach, Deborah Berg, Jianchang Lin, Alessandra Di Bacco, Ai-Min Hui, Helgi van de Velde, Paul G. Richardson,

Tópico(s)

Peptidase Inhibition and Analysis

Resumo

Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma.

Referência(s)